•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Duragesic Patch
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe your case:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Duragesic Patch


AddThis Social Bookmark Button
DOWNLOAD OUR INFORMATION PACKAGE

Injured by the Duragesic Patch?

Keywords: Duragesic | Lawyer | Death | Attorney | Injury | Overdose | Lawsuit

On July 15, 2005 the FDA issued a Public Health Advisory concerning the use of Duragesic Patches (Fentanyl transdermal) in response to reports of deaths in patients using the patch. The FDA is conducting an investigation into the deaths associated with these patches.

Our Dedicated Lawyers and Attorneys Have Years of Experience
Handling Defective Drug Lawsuits Such as Duragesic!

The Agency has been examining the circumstances of product use to determine if the reported adverse events may be related to inappropriate use of the patch or factors related to the quality of the product. It is possible that some patients and their health care providers may not be completely aware of the dangers of these potent narcotic drug products and the important recommendations regarding their safe use.

There has been an expanded recall of Duragesic Patches due to possible leaks. Janssen Pharmaceutica, the manufacturer of the Duragesic Patch notified healthcare professionals of an expanded recall of the Duragesic 75 mcg/h, in February 2004. Four additional lots have been subject to the present expanded recall. Some patches from the recalled lots may leak medication due to improper sealing of one of their edges.

Once You Fill Out The Duragesic Case Review Form, One of Our
Lawyers Skilled In Defective Drug Litigation Will Contact You.


If the medication leaks out of the patch, exposure to the medication can result in inadvertent ingestion or increased transdermal absorption of the active opiate component fentanyl, leading to potentially life-threatening complications. In addition, leakage of the medication could lead to inadequate dosing, resulting in treatment failure and/or opiate withdrawal.

The Duragesic Patch is indicated for the management of severe, chronic pain (such as cancer pain) that cannot be managed with less powerful drugs such as acetaminophen-opioid combinations and nonsteroidal analgesics.

Moreover, only patients who are already on and tolerant to opioid therapy, and require continuous opioid administration should use the patch. Approved by the U.S. Food and Drug Administration (FDA) in 1990, the Duragesic patch releases fentanyl, a strong opioid, through the skin at a fixed rate for 72 hours. The patch is available only by prescription.

If you or a loved one used a Duragesic Patch and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects lawyer / attorney.
Duragesic PatchRSS Feed

Warning on Transdermal Patches, MRIs

Mar 6, 2009 | Parker Waichman Alonso LLP
The U.S. Food and Drug Administration (FDA) has just issued information regarding the use of transdermal patches when undergoing MRI testing.  The medicated patches, which are applied to the skin and that contain aluminum or other metals in the backing of the patches, can contain metal which can overheat during an MRI scan and which can cause skin burns in the immediate area of the patch.The patches are meant to slowly deliver medication transdermally, or through the skin.  But, some...

Misleading Risperdal, Duragesic Patch Claims Prompt Fines in West Virginia Lawsuit

Mar 4, 2009 | Parker Waichman Alonso LLP
Risperdal maker Johnson & Johnson has been ordered by a West Virginia judge to pay a hefty fine over a 2003 letter to doctors that obfuscated the antipsychotic drug's diabetes risk. According to Bloomberg News, the same judge also assessed a smaller fine after finding that doctors were misled about the risks and benefits of the company's Duragesic pain patch.Risperdal is one of class of drugs called atypical antipsychotics.  Other atypical antipsychotics include Eli Lilly's Zyprexa,...

FDA Reviewing Narcotic Painkillers

Feb 10, 2009 | Parker Waichman Alonso LLP
The makers of two dozen opioid drugs, including Oxycontin, morphine, methadone and the Duragesic patch, have been ordered by the Food & Drug Administration (FDA) to develop Risk Evaluation and Mitigation Strategy (REMS) plans to reduce the misuse of their painkillers.  The FDA's latest action on these narcotic painkillers comes just days after the agency and the Centers for Disease Control (CDC) announced that they will be working together to look at the rising trend of accidental...

Alert for Duragesic, Other Fentanyl Pain Patches Issued by Health Canada

Jan 8, 2009 | Parker Waichman Alonso LLP
Health Canada has announced that the makers of Fentanyl Transdermal System patches are changing dosage guidelines in order to reduce the risk of fentanyl overdoses.  The products involved in this alert include Duragesic patches made by Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, as well as generic versions made by Cobalt Pharmaceuticals Inc., Novopharm Limited, Ranbaxy Pharmaceuticals Canada Inc.  and ratiopharm inc.The Duragesic and other similar pain...

More Duragesic Pain Patches Recalled

Jan 2, 2009 | Parker Waichman Alonso LLP
Once again, Johnson & Johnson is recalling some Duragesic Pain Patches because of a defect that could cause patients to overdose on fentanyl.  This is the second time in less than a year that Johnson & Johnson has recalled Duragesic patches.  A similar action was issued by the company just last February.The Duragesic and other similar pain patches are meant to treat persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age or older. Fentanyl is a...

More Duragesic Patch News